Attached files
| file | filename |
|---|---|
| EX-3.1 - EX-3.1 - International Stem Cell CORP | d43307dex31.htm |
| EX-3.2 - EX-3.2 - International Stem Cell CORP | d43307dex32.htm |
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): December 3, 2015
INTERNATIONAL STEM CELL CORPORATION
(Exact name of registrant as specified in its charter)
| Delaware | 000-51891 | 20-4494098 | ||
| (State or other jurisdiction of incorporation) |
(Commission File Number) |
(IRS Employer Identification Number) |
5950 Priestly Drive, Carlsbad, CA 92008
(Address of principal executive offices, including zip code)
(760) 940-6383
(Registrant’s telephone number, including area code)
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
| ITEM 5.03 | AMENDMENT OF ARTICLES OF INCORPORATION OR BYLAWS; CHANGE IN FISCAL YEAR |
As a result of conversion between November 2014 and November 2015 by the holders of all shares of Series H-1 and Series H-2 Preferred Stock to common stock, there were no longer any shares of Series H-1 and Series H-2 Preferred Stock outstanding. On December 3, 2015, the Company filed Certificates of Elimination for the Series H-1 and Series H-2 Preferred Stock. The Certificates of Elimination amended the provisions of the Certificate of Incorporation of the Company to eliminate the powers, designations, preferences, privileges, and other rights of the Series H-1 and Series H-2 Preferred Stock.
| ITEM 9.01 | FINANCIAL STATEMENTS AND EXHIBITS |
| (d.) | Exhibits |
| 3.1 | Certificate of Elimination for Series H-1 Preferred Stock | |
| 3.2 | Certificate of Elimination for Series H-2 Preferred Stock | |
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| International Stem Cell Corporation | ||
| By: | /s/ Mahnaz Ebrahimi | |
| Mahnaz Ebrahimi | ||
| Chief Financial Officer | ||
Dated: December 3, 2015